| THALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma of the central nervous system | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Suspended | ClinicalTrials |
| POMALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | colorectal neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | uterine sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | proctitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | systemic lupus erythematosus | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Crohn's disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute lymphoblastic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Burkitts lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Enrolling by invitation | ClinicalTrials |
| LENALIDOMIDE | Small molecule | marginal zone B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | renal cell carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | plasma cell leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | malnutrition | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Burkitts lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | immune system disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | ATC |
| THALIDOMIDE | Small molecule | coronary artery disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | fallopian tube cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | unspecified peripheral T-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | chronic pancreatitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | kidney cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | renal cell carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | systemic scleroderma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | systemic lupus erythematosus | CRL4(CRBN) E3 ubiquitin ligase modulator | 2.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Kaposi's sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Kaposi's sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | breast cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | prostate adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | polycythemia vera | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | colorectal neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | immune system disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | ATC |
| THALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Castleman disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | thyroid neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | amyotrophic lateral sclerosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | unspecified peripheral T-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | polycythemia vera | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | COVID-19 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | pancreatic carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasma cell leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 3.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Uterine Carcinosarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | kidney cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 0.5 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Central Nervous System Lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | breast cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Thalassemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Kaposi's sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | POEMS syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | congestive heart failure | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | metastatic colorectal cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | ankylosing spondylitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | HIV infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | primary myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | unspecified peripheral T-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | medulloblastoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | kidney cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | Ocular Melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | extranodal nasal NK/T cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | malignant glioma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| THALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | HIV-1 infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | pancreatic carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | graft versus host disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | MALT lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | discoid lupus erythematosus | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | kidney cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | B-cell neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | adult acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Thalassemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | central nervous system non-hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasma cell leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Suspended | ClinicalTrials |
| THALIDOMIDE | Small molecule | brain stem neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | cutaneous melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatitis C virus infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | colorectal adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myeloproliferative disorder | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| POMALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | prostate adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 3.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | pancreatic ductal adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | pancreatic neuroendocrine tumor | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | POEMS syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | cardiac amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | Ocular Melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | hereditary hemorrhagic telangiectasia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | anaplastic astrocytoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | hematopoietic and lymphoid cell neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | systemic scleroderma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | medulloblastoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | cutaneous lupus erythematosus | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | vascular malformation | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | uveitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | pancreatic ductal adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | cutaneous melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | liver cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasma cell leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | sclerosing cholangitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | radiculopathy | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | sickle cell anemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | appendix carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | malignant epithelial tumor of ovary | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | ankylosing spondylitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | liver cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | malignant colon neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | head and neck malignant neoplasia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | pulmonary fibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IBERDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | renal cell carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Sensorimotor neuropathy | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | ovarian cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Suspended | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | thyroid carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | lung cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | high grade B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | HIV infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | idiopathic pulmonary fibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | liver disease | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasmacytoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic myelomonocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | cutaneous lupus erythematosus | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | adult acute lymphoblastic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neuroblastoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | colorectal carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | prolymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| POMALIDOMIDE | Small molecule | metastatic malignant neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | non-small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | glioblastoma multiforme | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Kaposi's sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | anemia (phenotype) | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | esophageal cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Cough | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Crohn's disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Not yet recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | polycythemia vera | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | MALT lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Central Nervous System Neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | epilepsy | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | nodular sclerosis Hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | oral cavity cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasma cell leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | gastric cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Crohn's disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | primary systemic amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| IBERDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | sarcoidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | high grade B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | glioblastoma multiforme | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| LENALIDOMIDE | Small molecule | primary systemic amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic myelogenous leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | immune system disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | ATC |
| LENALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 2.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | AIDS | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | neuroendocrine neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | primary systemic amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | squamous cell carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| LENALIDOMIDE | Small molecule | anemia (phenotype) | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | HIV infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Epstein-Barr virus infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | complex regional pain syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | primary myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | Central Nervous System Neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | myeloproliferative disorder | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | non-small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | hepatocellular carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | gastric cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | kidney cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | malignant colon neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neuroblastoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | peritoneum cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | gliosarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Cutaneous T-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | neuroendocrine neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Langerhans Cell Histiocytosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | Central Nervous System Neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Suspended | ClinicalTrials |
| LENALIDOMIDE | Small molecule | malignant glioma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic myelomonocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| IBERDOMIDE | Small molecule | sarcoidosis | CRL4(CRBN) E3 ubiquitin ligase modulator | 2.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | central nervous system non-hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | pain | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Richter syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| THALIDOMIDE | Small molecule | liver cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | endometriosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | HIV wasting syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | peritoneum cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | idiopathic pulmonary fibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | marginal zone B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | ulcerative colitis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | rectum cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | complex regional pain syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | urethra cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | soft tissue sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | Crohn's disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | central nervous system non-hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | autism | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | non-Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| LENALIDOMIDE | Small molecule | prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | lung cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | Crohn's disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | uterine leiomyosarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Suspended | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Cachexia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | central nervous system non-hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | T-cell acute lymphoblastic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | graft versus host disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | metastatic prostate cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | bladder tumor | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | sinus histiocytosis with massive lymphadenopathy | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | lung cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | HIV infection | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic myelomonocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | Hypoalbuminemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | follicular lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | fallopian tube cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | Beta-thalassemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| IBERDOMIDE | Small molecule | Renal insufficiency | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | mature T-cell and NK-cell non-Hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Hodgkins lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | kidney neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | COVID-19 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | neoplasm of mature B-cells | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse intrinsic pontine glioma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | psoriasis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | metastatic colorectal cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | adult T-cell leukemia/lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | primary myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasmacytoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | essential thrombocythemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | plasmacytoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | Alzheimer disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | plasmacytoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | central nervous system non-hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 0.5 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | unspecified peripheral T-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | neuroblastoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | ovarian cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | anemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 4.0 | - | DailyMed |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Castleman disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | interstitial lung disease | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | MALT lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | polycythemia vera | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | amyotrophic lateral sclerosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Burkitts lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | melanoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | asymptomatic myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | glioma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | metastasis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | metastatic malignant neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | non-small cell lung carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Central Nervous System Neoplasm | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | primary myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | colorectal carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| THALIDOMIDE | Small molecule | myelofibrosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | prostate adenocarcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| POMALIDOMIDE | Small molecule | Waldenstrom macroglobulinemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | myelodysplastic syndrome | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | diffuse large B-cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| THALIDOMIDE | Small molecule | autoimmune thrombocytopenic purpura | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | urinary bladder cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Completed | ClinicalTrials |
| THALIDOMIDE | Small molecule | lung cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| IBERDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase modulator | 1.0 | Withdrawn | ClinicalTrials |
| POMALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | chronic lymphocytic leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| LENALIDOMIDE | Small molecule | acute myeloid leukemia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| LENALIDOMIDE | Small molecule | T-cell non-Hodgkin lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Mantle cell lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| LENALIDOMIDE | Small molecule | ovarian cancer | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| THALIDOMIDE | Small molecule | soft tissue sarcoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | AL amyloidosis | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 3.0 | Completed | ClinicalTrials |
| POMALIDOMIDE | Small molecule | pancreatic carcinoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Completed | ClinicalTrials |
| LENALIDOMIDE | Small molecule | Abnormality of blood and blood-forming tissues | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | lymphoma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 1.0 | Terminated | ClinicalTrials |
| LENALIDOMIDE | Small molecule | multiple myeloma | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| POMALIDOMIDE | Small molecule | hereditary hemorrhagic telangiectasia | CRL4(CRBN) E3 ubiquitin ligase inhibitor | 2.0 | Recruiting | ClinicalTrials |